ArticleACS omega2026
Inosine Exerts Glioprotective Effects against Lipopolysaccharide-Induced Damage in Primary Astrocyte Cultures: Role of the Adenosinergic System.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inosine is a purine nucleoside derived from adenosine metabolism that has been associated with neuroprotective and anti-inflammatory properties. The present study investigated the effects of inosine against lipopolysaccharide (LPS)-induced damage in primary astrocyte cultures and explored the potential contribution of adenosinergic signaling to these responses. LPS exposure impaired astrocyte viability and proliferation, altered cholinergic and purinergic enzyme activities, disrupted redox homeostasis, and increased the level of IL-6 release. Inosine treatment attenuated these alterations, restoring cell viability and proliferation, modulating acetylcholinesterase and ectonucleotidase activities, reducing oxidative damage, and preventing the LPS-induced increase in IL-6 levels. Mechanistic studies using pharmacological modulation of the adenosinergic system revealed that blockade of adenosine receptors interfered with some of the antioxidant effects of inosine, particularly those related to antioxidant enzyme activity, whereas its effects on cytokine modulation remained unchanged. Additional experiments using selective A2A receptor antagonists provided preliminary evidence that A2A receptor signaling may be involved in the antioxidant-related effects observed under inosine-treated conditions. Collectively, these findings demonstrate that inosine exerts multitarget protective effects in astrocytes, modulating oxidative stress, neurotransmission-related pathways, and inflammatory responses. These results support its potential as a promising strategy for restoring astrocyte homeostasis under neuroinflammatory conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.